A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Korean and Taiwanese Subjects With Chronic Genotype 1 HCV Infection
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 24 Oct 2017 Results assessing the safety and efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV Infected Chinese Population (n=206) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 13 Oct 2017 Status changed from active, no longer recruiting to completed.
- 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.